SCHEMBL30765697

SCHEMBL30765697

O=C(Cn1c(-c2ccccc2)ncc(NC(=O)CCc2ccccc2)c1=O)NCc1cc2cnccc2[nH]1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 6/20 0.43
NTRK1 P04629 2/20 0.43
NTRK3 Q16288 1/20 0.43
CMA1 P23946 2/20 0.42
CTRC Q99895 2/20 0.42
KDM6B O15054 1/20 0.42
KDM4D Q6B0I6 1/20 0.42
KDM4C Q9H3R0 1/20 0.42
EGLN3 Q9H6Z9 1/20 0.42
ELANE P08246 3/20 0.42
HDAC6 Q9UBN7 1/20 0.42
F3 P13726 2/20 0.42
PRSS1 P07477 2/20 0.40
IL1B P01584 1/20 0.40
CASP1 P29466 1/20 0.40
PRSS2 P07478 1/20 0.40
PRSS3 P35030 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765502 0.89 CASP1 (0.40) F2NTRK1NTRK3CMA1CTRC
SCHEMBL31558568 0.87 NTRK1 (0.45) NTRK1NTRK3CMA1CTRCELANE
SCHEMBL30766049 0.86 NTRK1 (0.43) F2NTRK1NTRK3CMA1CTRC
SCHEMBL30765583 0.86 F2 (0.40) F2NTRK1NTRK3CMA1CTRC
SCHEMBL30765820 0.86 CMA1 (0.40) F2NTRK1CMA1CTRCELANE
Hydrochloric Acid SCHEMBL30765434 0.85 NTRK1 (0.43) F2NTRK1NTRK3CMA1CTRC
SCHEMBL30765875 0.85 F2 (0.42) F2NTRK1CMA1CTRCF3
SCHEMBL30765955 0.85 TDP1 (0.40) NTRK1NTRK3CMA1CTRCELANE
SCHEMBL31558453 0.85 NTRK1 (0.48) F2NTRK1NTRK3CMA1CTRC
SCHEMBL30765484 0.84 CMA1 (0.53) NTRK1NTRK3CMA1CTRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed